Consensus statement on dementia education and training in Europe

Journal of Nutrition, Health and Aging

Volumn 14, Issue 2, 2010, Pages 131-135

  Tsolaki, M ^a   Papaliagkas, V ^a   Anogianakis, G ^a   Bernabei, R ^b   Emre, M ^c   Frolich, L ^d   Visser, P J ^e   Michel, J P ^f   Pirttila, T ^g   Olde Rikkert, M ^h   Soininen, H ^g   Sobow, T ⁱ   Vellas, B ^j   Verhey, F ^e   Winblad, B ^k  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b CATHOLIC UNIVERSITY   (Italy)

^c ISTANBUL UNIVERSITY   (Turkey)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f UNIVERSITY OF GENEVA   (Switzerland)

^g UNIVERSITY OF EASTERN FINLAND   (Finland)

^h RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ MEDICAL UNIVERSITY OF LODZ   (Poland)

^j UNIVERSITÉ DE TOULOUSE   (France)

^k University of Toulouse ^*  (Sweden)

more..

Author keywords

Alzheimer's disease; Consensus statement; Dementia; Education; Europe

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; CONSENSUS DEVELOPMENT; DEMENTIA; DRUG INDUSTRY; EUROPE; HEALTH CARE PERSONNEL; MEDICAL EDUCATION; MEDICAL STUDENT; PHYSICIAN; PRIORITY JOURNAL; STRUCTURED QUESTIONNAIRE; TRAINING; ATTITUDE TO HEALTH; CONFERENCE PAPER; CURRICULUM; DENTAL STUDENT; HUMAN; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE; PRACTICE GUIDELINE; QUESTIONNAIRE; STANDARD; STATISTICS;

CURRICULUM; DEMENTIA; EDUCATION, MEDICAL; EDUCATION, MEDICAL, CONTINUING; EDUCATION, MEDICAL, GRADUATE; EUROPE; GUIDELINES AS TOPIC; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INTERDISCIPLINARY COMMUNICATION; PATIENT CARE TEAM; QUESTIONNAIRES; STUDENTS, DENTAL;

EID: 77952303295     PISSN: 12797707     EISSN: 17604788     Source Type: Journal    
DOI: 10.1007/s12603-009-0238-z     Document Type: Article

References (18)

1. Alzheimer A. Über eine eigenartige Erkrankung der Hirnrinde Allgemeine Zeitschrift fur Psychiatrie und Psychisch-gerichtliche Medizin. 1907
2. Wimo A, Ljunggren G, Winblad B. Costs of dementia and dementia care: a review. Int J Geriatr Psychiatry 1997;12:841-56
3. Plassman BL, Langa KM, Fisher GG, Heeringa SG, Weir DR, Ofstedal MB, Burke JR, Hurd MD, Potter GG, Rodgers WL, Steffens DC, McArdle JJ, Willis RJ, Wallace RB. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29:125-132.
4. Ferri C, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Alzheimer's Disease International: Global prevalence of dementia: a Delphi consensus study. Lancet. 2005;366:2112-2117.
5. Wimo A, Winblad, B, Stoffler A, Wirth Y, Mobius HJ. Resource utilisation and cost analysis of memantine in patients with moderate to severe Alzheimer's disease. Pharmacoeconomics. 2003;21:327-340.
6. Fillit H, Hill J. Economics of dementia and pharmacoeconomics of dementia therapy. Am J Geriatr Pharmacother. 2005;3:39-49.
7. Meek PD, McKeithan K, Schumock GT. Economic considerations in Alzheimer's disease. Pharmacotherapy. 1998;18:68-73.
8. Waldemar G, Dubois B, Emre M, Scheltens P, Tariska P, Rossor M. Diagnosis and management of Alzheimer's disease and other disorders associated with dementia. The role of neurologists in Europe. European Federation of Neurological Societies. Eur J Neurol. 2000;7:133-144.
9. National Institute for Clinical Excellence. Guidance on the use of donepezil, rivastigmine and galantamine for the treatment of Alzheimer's disease. Available from URL: http://www.nice.org.uk/pdf/ALZHEIMER-full-guidance. df [Accessed 16 June 2009].
10. Ruof J, Mittendorf T, Pirk O, von der Schulenburg JM. Diffusion of innovations: treatment of Alzheimer's disease in Germany. Health Policy. 2002;60:59-66.
11. Caltagirone C, Bianchetti A, Di Luca M, Mecocci P, Padovani A, Pirfo E, Scapicchio P, Senin U, Trabucchi M, Musicco M; Italian Association of Psychogeriatrics. Guidelines for the Treatment of Alzheimer's Disease from the Italian Association of Psychogeriatrics. Drugs & Aging 2005;22:1-26.
12. Patterson CJ, Gauthier S, Bergman H, Cohen CA, Feightner JW, Feldman H, Hogan DB. The recognition, assessment and management of dementing disorders: conclusions from the Canadian Consensus Conference on Dementia. CMAJ. 1999;15: S1-15.
13. Hogan DB, Bailey P, Black S, Carswell A, Chertkow H, Clarke B, Cohen C, Fisk JD, Forbes D, Man-Son-Hing M, Lanctôt K, Morgan D, Thorpe L. Diagnosis and treatment of dementia: 4. Approach to management of mild to moderate dementia. CMAJ. 2008;179:787-793.
14. Burns A, O'Brien J, BAP Dementia Consensus group, Auriacombe S, Ballard C, Broich K, Bullock R, Feldman H, Ford G, Knapp M, McCaddon A, Iliffe S, Jacova C, Jones R, Lennon S, McKeith I, Orgogozo JM, Purandare N, Richardson M, Ritchie C, Thomas A, Warner J, Wilcock G, Wilkinson D; British Association for Psychopharmacology. Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol. 2006;20:732-755.
15. Hasselbalch SG, Baloyannis S, Denislic M, Dubois B, Oertel W, Rossor M, Tsiskaridze A, Waldemar G. Education and training of European neurologists in dementia. Eur J Neurol. 2007;14:505-509.
16. Pfizer Pharmaceuticals. Model Scenario and course on the formation of keypersons. Knowledge of and attitudes to Dementia, 1997.
17. Nivalis, Circle of care for Professionals and for Relatives. The trained professional Janssen Cilag Academy.
18. Tsolaki M, Papaliagkas V et al. Education of Professionals on Alzheimer's Disease. Eur J of Neurol. 2005;12:294.